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ABSTRACT: As a part of our efforts to expand chemical diversity in the Carbonic Anhydrases Inhibitors (CAIs), three small 
series of polyheterocyclic compounds (4-6) featuring the primary benzenesulfonamide moiety linked to bi/tricyclic scaf-
folds were investigated. Highly effective inhibitors against the target tumor-associated hCA IX (low nanomolar/subnano-
molar potency levels), showing significant functional selectivity profile towards hCA I, II and IV isozymes were identified. 
Molecular docking studies clarified the reasons behind the activity and selectivity of the new compounds. 
Introduction 
The metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) is 
widespread in organisms all over the phylogenetic tree and 
catalyzes a simple physiological reaction, the interconver-
sion between CO2 and bicarbonate, with the generation of 
a proton.1 CA inhibition finds pharmacological applications 
in several fields including diuretics, antiglaucoma, anti-
convulsant, and anticancer agents.2 Sulfonamides and 
their bioisosteres (sulfamates, sulfamides), were reported 
as pharmacologically relevant CA inhibitors (CAIs).3  
Due to the ubiquity of such enzymes, the selective inhibi-
tion and polypharmacology of inhibitors is an important 
aspect of all drug design campaigns.3 Several drug design 
strategies have been reported ultimately based on the tail 
approach4 for obtaining sulfonamides/dithiocarbamates, 
which exploit more external binding regions within the en-
zyme active site (in addition to coordination to the metal 
ion), thus leading to isoform-selective compounds. Thus, 
the exploration of novel scaffolds may expand chemical di-
versity aiding the development of novel classes of CAIs 
with the desired pharmacologic properties. In this connec-
tion, we recently reported a novel class of tricyclic ben-
zenesulfonamides 1a-e featuring the benzothiopyrano[4,3-
c]pyrazole (1a−c) and pyridothiopyrano[4,3-c]pyrazole 
(1d−e) systems (Chart 1),5 designed as geometrically con-
strained analogues of celecoxib (CLX) and valdecoxib 
(VLX), originally launched as cyclooxygenase 2 (COX-2) 
specific inhibitors, and later shown also to act as potent 
CAIs.6  
Compounds 1a-e behaved as selective CAIs without any in-
hibitory effect on COX-2. In addition, the most interesting 
feature was their capability to predominantly exert strong 
inhibition of only human (h) isoforms hCA I and II, 
whereas their inhibitory activity against hCA III, IV, VA, 
VB, VI, VII, IX, XII, XIII, and XIV was up to 2 orders of mag-
nitude lower, potentially resulting in a lower occurrence of 
side effects. X-ray crystallographic studies performed on 1e 
(Chart 1) in complex with hCA II, combined with homology 
modeling, rationalize this inhibition profile: compound 1e 
is buried deep into the active site with the sulfonamide ni-
trogen directly bound to the zinc ion; the sulfur atom is out 
of the active site and not directly involved in any interac-
tion with the enzyme, only producing a pucker in the ring 
geometry; the hydrophobic tricyclic scaffolds protrudes 
out of the active site, where it is stabilized by van der Waals 
interactions with hydrophobic residues lining the active 
site cavity. According to this interaction mode, the differ-
ences in affinity for hCA I and II, with respect to hCA IX 
and XII, might be ascribed to point mutations in amino 
  
Chart 1. Structure of previously described (1-3) and newly synthesized (4-6) CAIs. 
acid sequences that produce a reduction in hydrophobicity 
in the hydrophobic pockets within the active site of hCA 
IX and XII.5 More recently, class 1 was further investigated 
by moving the benzenesulfonamide function from position 
1 to position 2 of the pyrazole system (2a-d) (Chart 1).7 Con-
temporaneously, two diverse heteropolycyclic scaffolds 
from our in-house database, structurally similar to the py-
razoles of types 1 and 2, that is benzothiopyranopyrimidine 
and pyridothiopyrano-pyrimidine, were decorated with a 
benzenesulfonamide moiety at the 2-position of the tricy-
clic system by an NH linker, yielding compounds 3a–e 
(Chart 1)7 An excellent inhibitory activity against isoforms 
hCA II, IX, and XII was shown by most of the new sulfona-
mides 2 and 3, although without high selectivity profile 
among the various isoforms.7 
As a part of our efforts to expand chemical diversity in the 
CAIs with the aim of identifying potent selective inhibitors, 
in the present work, three small series of polyheterocyclic 
compounds (4-6) featuring the classical primary 
benzenesulfonamide moiety crucial for the binding to the 
catalytically metal ion, were synthesized and biologically 
evaluated. Specifically, in all the novel classes the sulfur 
bridge was replaced with the bioisosteric methylene as our 
previous studies highlighted that the sulfur atom was un-
necessary for the interaction of 1e with the enzyme.5 The 
7-substituted-4-(4,5-dihydro-1H-pyrazolo[3,4-
f]quinazolin-1-yl)benzenesulfonamides 4a-c (Chart 1) 
maintained a 5,6,6 tricyclic system analogous to derivatives 
1-3, but an additional nitrogen atom was introduced in the 
pyridine nucleus, converting it into a pyrimidine, possibly 
providing an additional or alternative interaction point 
with the enzyme. 
The bicyclic tetrahydroindazole (5a-c, Chart 1) and 
tetrahydroquinazole (6a-c, Chart 1) derivatives were con-
ceived as a structural simplification of compounds 1 and 3, 
respectively, in which the phenyl- or pyrido-fused moiety 
was removed and a carbonyl group was added in the non-
aromatic ring. The crucial benzenesulfonamide function 
was maintained, directly linked at 1-position of the pyra-
zole ring (5a-c, Chart 1) or linked at 2-position of the py-
rimidine ring by an NH spacer (6a-c, Chart 1), in strict sim-
ilarity to derivatives 1 and 3, respectively. 
Finally, tricyclic compounds 4a-c and bicyclic derivatives 
5a-c and 6a-c were decorated with methyl or phenyl 
groups (R, R1, and R2) to evaluate the effect of these sub-
stituents on the efficacy and selectivity towards different 
CA isoenzymes. 
Chemistry 
The key intermediates for the synthesis of the target 
compounds 4a-c, 5a-c and 6a-c were the dimethyla-
minomethylene derivatives 7a-c, which were prepared by a 
previously reported procedure with slight modifications 
(Scheme 1).8,9 Briefly, the commercially available 5-substi-
tuted-1,3-cyclohexandiones were reacted with an excess of 
N,N-dimethylformamide dimetylacetal (DMF-DMA) at 100 
°C for one hour to furnish the intermediates 7a-c in quan-
titative yield.  
The 1,3-bielectrophilic reaction of 7a with nucleophilic re-
agents, formamidine, acetamidine or benzamidine hydro-
chloride, in refluxing ethanol for 15-30 hours (TLC analysis) 
led to the pyrimidine derivatives 8a-c,9 that were then re-
acted with an excess of DMF-DMA at 100 °C for one hour 
to obtain the intermediates 9a-c in very good yields.10,11 De-
rivatives 9a-c were then solubilized in ethanol and reacted 
with a slight excess of commercial4-hydrazinebenzenesul-
fonamide hydrochloride, basically according to described 
procedures.12-14 The reaction mixture was heated to 80 °C 
for 20 hours and, after cooling, the obtained crude com-
pounds 4a-c were purified by flash chromatography 
(Scheme 1). Similarly, the synthesis of the new bicyclic 
tetrahydroindazoles 5a-c and tetrahydroquinazoles 6a-c 
took advantage of the reactivity of derivatives 7a-c8 
(Scheme 1). When 7a-c were reacted with a slight excess of 
the commercially available 4-hydrazinebenzenesulfona-
mide hydrochloride in ethanol at 80 °C for 5-20 hours (TLC 
analysis), compounds 5a-c were obtained and purified by 
recrystallization from ethanol (Scheme 1). Instead, reaction 
of intermediates 7a-c with the guanidine 107 in refluxing n-
butanol, in the presence of sodium hydroxide for 16 hours, 
furnished compounds 6a-c, then purified by recrystalliza-
tion from ethanol (Scheme 1).  
Results and Discussion 
All the newly synthesized compounds 4a-c, 5a-c and 6a-c 
were investigated for their enzyme inhibitory capacity 
against four physiologically relevant CA isoforms, the hu-
man (h) hCA I, II, IV, and IX (Table 1), by a stopped-flow 
CO2 hydrase assay.15 Acetazolamide (AAZ, 5-acetamido-
1,3,4-thiadiazole-2-sulfonamide) was used as standard drug 
 Scheme 1. 
 
Reagents and conditions: (i) DMF-DMA, 100 °C; (ii) formamidine, acetamidine or benzamidine hydrochloride, refluxing etha-
nol; (iii) DMF-DMA, 100 °C; (iv) 4-hydrazinebenzenesulfonamide hydrochloride, ethanol, 80 °C; (v) 4-hydrazinebenzenesulfona-
mide hydrochloride, refluxing ethanol; (vi) concentrated HCl/50% cyanamide water solution, 100 °C; (vii) NaOH, refluxing n-
butanol. 
in the assay.15 From a general point of view, the data listed 
in Table 1 show that the bioisosteric substitution of the sul-
fur bridge with a methylene moiety leads to potent CAIs, 
confirming our previous findings of the absence of a direct 
involvement of the sulfur in the interaction with the en-
zyme. All the newly synthesized compounds are highly ef-
fective inhibitors against the target tumor-associated hCA 
IX, exhibiting potency levels in the low nanomolar/subna-
nomolar range (Ki range from 7.3 nM to 0.55 nM), with an 
activity gain of several times compared to the reference 
AAZ (Ki 25.8 nM); the cytosolic isoform hCA I was moder-
ately inhibited by compounds 4-6, whereas diverse activi-
ties against isozymes II and IV were observed. All deriva-
tives showed to act as preferential inhibitors of hCA IX, 
with selectivity ratios ranging from 61.3 to >1370 against 
hCA I, from 7.12 to 577 for hCA II and from 1.8 to 359 for 
hCA IV. Specifically, switching the pyridothiopyranopy-
rimidine of 1d-e to the pyrazolo-dihydroquinazoline of 4a-
c affected hCA inhibition depending on the substituent at 
7-position: the unsubstituted compound 4a showed a gain 
in activity towards all the isoenzyme tested, but particu-
larly for the isoform IX. Insertion of a 7-methyl or 7-phenyl 
group on 4a, yielding compounds 4b-c, resulted in a mod-
est decrease in potency hCA IX inhibition (4a Ki 0.57 nM, 
4b Ki 7.0 nM, 4c Ki 7.3 nM). However, the installation of 
the 7-phenyl substituent conferred a high degree of selec-
tivity to hCA IX when compared the other tested hCAs. 
Sub-nanomolar inhibition against the isoform IX was 
achieved by all the compounds featuring a simplified scaf-
fold (5b-c, 6a-c, Ki values ranging from 0.55 to 0.89 nM), 
independent by the decoration of the central nucleus, with 
the only exception of 5a (Ki 5.2 nM). The isoforms hCA I 
and II were scarcely (hCA I) or effectively (hCA II) inhib-
ited by compounds 5-6 [Ki values spanning between 272.2 
nM to 746.3 nM (the sole exception to this trend is 6a, Ki 
63.9 nM) and 5.2 nM to 8.6 nM (the sole exception to this 
trend is 5a, Ki 78.2 nM), for hCA I and hCA II, respectively), 
while sparing Ki values were obtained for the membrane-
bound hCA IV. 
To clarify the reasons behind the displayed activity and se-
lectivity of the newly designed compounds, molecular 
docking studies were undertaken for ligands 4c, 5c, and 6c 
as representative compounds of the three series. For this 
purpose, the latest version of AutoDock4.2 (AD4)16 was 
employed in combination with the available high- 
resolution crystal structure of hCA IX bound to an inhibi-
tor (PDB code 5FL4, 1.82 Å).17 Taking into account that a 
zinc atom participates to the binding event, the recently 
released AutoDock4(Zn) force field was employed,18 which 
greatly enhances the accuracy of the pose prediction when 
docking zinc-chelating compounds. In particular, a spe-
cialized potential was introduced into the standard Auto-
Dock force field to describe both the geometric and 
energetic components of the interactions of zinc-
 Table 1. Inhibition of hCA Isoforms I, II, IV, IX with Sulfonamides 4a-c, 5a-c and 6a-c, and AAZ as reference standard by a 
Stopped-Flow CO2 Hydrase Assay.  
 
    Ki (nM)a 
cpd R R1 R2 
hCA I  
[hCA I/hCA IX]b 
hCA II 
[hCA II/hCA IX]b 
hCA IV 
[hCA IV/hCA IX]b 
hCA IX 
1dc H - - 193 72 328 2340 
1ec CH3 - - 155 49 7500 3250 
4a H - - 73.5 [129] 4.6 [8.1] 7.1 [12.5] 0.57 
4b CH3 - - 429.0 [61.3] 68.6  [9.8] 581.3 [83] 7.0 
4c C6H5 - - >10000 [>1370] 4209.2 [577] 7228.7 [990] 7.3 
5a - H H 746.3 [143.5] 78.2 [15] 9.5 [1.8] 5.2 
5b - CH3 CH3 272.2 [309] 8.6 [9.8] 39.7 [45] 0.88 
5c - H C6H5 295.7 [405] 5.2 [7.1] 213.7 [293] 0.73 
6a - H H 63.9 [116] 5.2 [9.45] 73.0 [132.7] 0.55 
6b - CH3 CH3 633.4 [712] 8.2 [9.2] 319.4 [359] 0.89 
6c - H C6H5 686.3 [869] 6.0 [7.6] 78.0 [98.7] 0.79 
AAZ    250 12.1 74 25.8 
aMean from three different assays. Errors were in the range of ± 5-10% of the reported values (data not shown). b Ki ratio for the 
indicated enzyme isoforms. c Data from ref 5.
coordinating ligands. To test the predictive power of the 
protocol, the co-crystal ligand of the selected X-ray com-
plex, a sulfonamide inhibitor, was re-docked into its cog-
nate receptor structure. Indeed, AD4 yielded a pose which 
is virtually superimposable to the experimental one (root 
mean squared deviation of 0.72 Å). The encouraging dock-
ing results prompted the employment of the aforemen-
tioned AD4 force field for the docking of the selected hCAs 
inhibitors into the hCA IX structure. Analysis of the 
achieved results revealed that 4c, 5c, and 6c, chelate the 
catalytic zinc in the active site through their negatively 
charged nitrogen of the sulfonamide moiety, which is con-
sistent with the pose of all the other sulfonamides com-
plexed to CAs. Furthermore, the sulfonamide in each com-
pound is well positioned to form an H-bond with the back-
bone NH of T200. Apart from these shared interactions, 
the different core structure of the three selected CA inhib-
itors induces different interaction patterns with the rest of 
the protein structure. Specifically, 4c (Figure 1a) would 
preferentially adopt a conformation in which the two ni-
trogens of the pyrimidine ring accept a double H-bond 
from the Q71 and Q92 side-chains. Supposedly, the tight 
anchoring provided by the double H-bonding interaction 
might explain the high affinity of 4c for hCA IX. Interest-
ingly, the pendant phenyl ring of 4c is lodged in a hydro-
phobic gorge lined by L91, L123 and V130 residues. These 
residues belong to a so-called “hot spot” region which plays 
a key role in the compound selectivity being highly variable 
in terms of sequence and, consequently, three-dimensional 
conformation, within each CA isoenzyme.19 In this respect, 
it could be argued that the bulky and lipophilic phenyl sub-
stituent may not be easily allocated in the rather narrow 
“hot spot” gorge of hCA I and hCA II, accounting for the 
lower inhibitory activity displayed by 4c (Figures 1b, 1c) 
against these latter two isoenzymes. On the other hand, 
hCA IV features a “hot spot” region lined by rather hydro-
philic residues: N79, K95, and E127, in which the phenyl 
substituent would not engage favorable contacts.20 Com-
pounds 5c and 6c, regardless of their own chirality, share a 
common binding mode (Figure 1d and Figure S1 in Sup-
porting Information) taking favorable van der Waals con-
tacts with Q92, V130, L199, T201, and P203 residues. These 
data would indicate the absence of an enantio-discriminat-
ing binding of these compounds. Interestingly, a similar 
binding pose was also experimentally verified for the other 
co-crystal ligands of hCA IX.17,19 Moreover, their phenyl 
moiety points towards the same hydrophobic “hot spot” 
cleft described earlier. Thus, the selectivity of 5c and 6c to 
hCA IX could also be ascribed to a difficulty in allocating 
bulky and lipophilic substituents in the cleft of other hCAs. 
The strong enhancement of potency displayed by most of 
the newly synthesized derivatives against hCA IX, 
  
Figure 1. (A) 4c/hCA IX (PDB 5FL4)17 complex. The protein is depicted as cyan ribbons and sticks while the ligand as orange sticks. 
(B) 4c hCA IX docked binding pose within the hCA I (PDB 4WUP)21 structure. The protein is depicted as green ribbons and its 
molecular surface in gray. The ligand is represented as orange sticks and its molecular surface in yellow. (C) 4c hCA IX docked 
binding pose within the hCA II (PDB 3QYK)22 structure. The protein is depicted as light blue ribbons and its molecular surface in 
gray. The ligand is represented as orange sticks and its molecular surface in yellow. (D) Superimposition of the docked poses of 5c 
(pink sticks) and 6c (blue sticks) in the hCA IX active site. The protein is depicted as cyan ribbons and sticks. In panels A and D 
important residues are labeled. H-bonds are shown in red dashed lines while coordination bonds in green dashed lines. The images 
were generated using the UCSF Chimera software.23 
combined with their significant functional selectivity pro-
files, could be seen with interest for the design of novel 
anti-cancer agents with limited side effects. Indeed, due to 
its key role as a survival factor for tumor cells and its in-
volvement in insurgence of resistance to classical anti-
cancer treatments, CA IX represents an excellent drug tar-
get for the development of novel cancer therapeutic ap-
proaches. 
Experimental Section 
Chemistry. General directions are in the SI. The purity of 
tested compounds is ≥95% (HPLC analysis). 
The following intermediates were obtained according to 
methods previously described: 2-[(dimethylamino)meth-
ylene]cyclohexan-1,3-dione 7a, 2-[(dimethylamino)meth-
ylene]-5,5-dimethylcyclohexan-1,3-dione 7b, and 2-[(dime-
thylamino)methylene]-5-phenylcyclohexan-1,3-dione 7c;8 
2-methyl-7,8-dihydroquinazolin-5(6H)-one 8b, 2-phenyl-
7,8-dihydroquinazolin-5(6H)-one 8c;9 6-[(dimethyla-
mino)methylene]-2-methyl-7,8-dihydroquinazolin-5(6H)-
one 9b;10 6-[(dimethylamino)methylene]-2-phenyl-7,8-di-
hydroquinazolin-5(6H)-one 9c;11 N-(4-aminosulfonyl)phe-
nylguanidine carbonate 10.7 
General procedure for the synthesis of 7-substituted 
4-(4,5-dihydro-1H-pyrazolo[3,4-f]quinazolin-1-yl)ben-
zenesulfonamides 4a-c. The appropriate derivative 9a-c 
(7.o mmol) was solubilized in ethanol (3-5 mL) and added 
with 1.851 g (8.3 mmol) of 4-hydrazinebenzenesulfonamide 
hydrochloride. The reaction mixture was heated to 80 °C 
for 20 hours. After cooling, the obtained solid was purified 
by flash chromatography on silica gel column (petroleum 
ether 40–60 °C/ethyl acetate 1:9 as the eluting system) to 
furnish the desired compounds 4a-c (yields, physical, and 
spectral data are reported in SI).  
General procedure for the synthesis of 6-substituted 
4-(4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzene-
sulfonamides 5a-c. The appropriate derivative 7a-c8 (6.0 
mmol) was solubilized in ethanol (3-5 mL) and added with 
1.606 g (7.2 mmol) of 4-hydrazinebenzenesulfonamide hy-
drochloride. The reaction mixture was heated to 80 °C for 
5-20 hours (TLC analysis). After cooling, the obtained solid 
was purified by recrystallization from ethanol to give the 
desired compounds 5a-c (yields, physical, and spectral data 
are reported in SI).  
General procedure for the synthesis of 7-substituted 
4-[(5-oxo-5,6,7,8-tetrahydroquinazolin-2-
yl)amino]benzenesulfonamides 6a-c. Compounds 7a-
c8 (1.0 mmol) were solubilized in n-BuOH (3-5 mL) and 
added with 0.300 g (1.0 mmol) of 4-guanidinobenzenesul-
fonamide carbonate 10 and 0.080 g (2.0 mmol) of NaOH. 
The reaction mixture was heated up to 120 °C and left to 
stir for 16 hours (TLC analysis). After cooling, the obtained 
crude solid compounds 6a-c were purified by recrystalliza-
tion from ethanol (yields, physical, and spectral data are 
reported in SI).  
7,8-Dihydroquinazolin-5(6H)-one 8a. 2-[(Dimethyla-
mino)methylene]cyclohexan-1,3-dione 7a (1.00 g, 6.0 
mmol) was solubilized in 10 mL of EtOH and added with 
0.480 g (6.0 mmol) of formamidine hydrochloride. The re-
action mixture was heated to 100 °C for 5 hours. After cool-
ing the solid obtained was purified by flash-chromatog-
raphy on silica gel (petroleum ether 40-60/ethyl acetate 1:9 
as the eluting system) to furnish 8a as a yellow oil (yield 
25%; spectral data are reported in SI).  
6-((Dimethylamino)methylene)-7,8-dihydro-
quinazolin-5(6H)-one 9a. Compound 8a (0.355 g, 2.4 
mmol) was dissolved in 8 mL (3.6 mmol) of DMF-DMA and 
heated to 100 °C for about 1 hour. After cooling, the ob-
tained suspension was triturated with ethyl ether to yield 
9a as a yellow solid, which was used in the next step with-
out further purification (yield 95%; physical, and spectral 
data are reported in SI).  
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